We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Ranked Momentum Stocks to Buy for February 21st
Read MoreHide Full Article
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st:
CNA Financial Corporation (CNA - Free Report) : This provider of commercial property and casualty insurance products has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.7% over the last 60 days.
Electromed, Inc. (ELMD - Free Report) : This manufacturer of airway clearance therapy and related products has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
Pacira BioSciences, Inc. (PCRX - Free Report) : This provider ofnon-opioid pain management and regenerative health solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% over the last 60 days.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) : This biopharmaceutical company carries a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.
Regeneron Pharmaceuticals, Inc. Price and Consensus
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Top Ranked Momentum Stocks to Buy for February 21st
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st:
CNA Financial Corporation (CNA - Free Report) : This provider of commercial property and casualty insurance products has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.7% over the last 60 days.
CNA Financial Corporation Price and Consensus
CNA Financial Corporation price-consensus-chart | CNA Financial Corporation Quote
CNA Financial’s shares gained 10% over the last one month above the S&P 500’s increase of 1.6%. The company possesses a Momentum Score of A.
CNA Financial Corporation Price
CNA Financial Corporation price | CNA Financial Corporation Quote
Electromed, Inc. (ELMD - Free Report) : This manufacturer of airway clearance therapy and related products has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
Electromed, Inc. Price and Consensus
Electromed, Inc. price-consensus-chart | Electromed, Inc. Quote
Electromed’s shares gained 21.1% over the last one month. The company possesses a Momentum Score of A.
Electromed, Inc. Price
Electromed, Inc. price | Electromed, Inc. Quote
Pacira BioSciences, Inc. (PCRX - Free Report) : This provider ofnon-opioid pain management and regenerative health solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% over the last 60 days.
Pacira Pharmaceuticals, Inc. Price and Consensus
Pacira Pharmaceuticals, Inc. price-consensus-chart | Pacira Pharmaceuticals, Inc. Quote
Pacira BioSciences’ shares gained 12.4% over the last one month. The company possesses a Momentum Score of A.
Pacira Pharmaceuticals, Inc. Price
Pacira Pharmaceuticals, Inc. price | Pacira Pharmaceuticals, Inc. Quote
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) : This biopharmaceutical company carries a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.
Regeneron Pharmaceuticals, Inc. Price and Consensus
Regeneron Pharmaceuticals, Inc. price-consensus-chart | Regeneron Pharmaceuticals, Inc. Quote
Regeneron Pharmaceuticals’ shares gained 9.7% over the last one month. The company possesses a Momentum Score of A.
Regeneron Pharmaceuticals, Inc. Price
Regeneron Pharmaceuticals, Inc. price | Regeneron Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>